144 related articles for article (PubMed ID: 24326823)
21. Accuracy of classifying poorly differentiated non-small cell lung carcinoma biopsies with commonly used lung carcinoma markers.
Zachara-Szczakowski S; Verdun T; Churg A
Hum Pathol; 2015 May; 46(5):776-82. PubMed ID: 25776027
[TBL] [Abstract][Full Text] [Related]
22. Non-Small-cell Lung Cancer Patients With Adenocarcinoma Morphology Have a Better Outcome Compared With Patients Diagnosed With Non-Small-cell Lung Cancer Favor Adenocarcinoma.
Shiran I; Heller E; Jessel S; Kamer I; Daniel-Meshulam I; Navon R; Urban D; Onn A; Bar J
Clin Lung Cancer; 2017 May; 18(3):316-323.e1. PubMed ID: 28237243
[TBL] [Abstract][Full Text] [Related]
23. Excision-repair-cross-complement-1 protein as a prognostic factor in patients with advanced non-small cell lung cancer treated with platinum-based first-line chemotherapy.
Vassalou H; Stathopoulos E; Fiolitaki G; Koutsopoulos A; Voutsina A; Georgoulias V; Mavroudis D
Lung Cancer; 2013 Nov; 82(2):324-9. PubMed ID: 23993732
[TBL] [Abstract][Full Text] [Related]
24. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study.
Cappuzzo F; Ciuleanu T; Stelmakh L; Cicenas S; Szczésna A; Juhász E; Esteban E; Molinier O; Brugger W; Melezínek I; Klingelschmitt G; Klughammer B; Giaccone G;
Lancet Oncol; 2010 Jun; 11(6):521-9. PubMed ID: 20493771
[TBL] [Abstract][Full Text] [Related]
25. A trial of autologous ex vivo-expanded NK cell-enriched lymphocytes with docetaxel in patients with advanced non-small cell lung cancer as second- or third-line treatment: phase IIa study.
Yang YJ; Park JC; Kim HK; Kang JH; Park SY
Anticancer Res; 2013 May; 33(5):2115-22. PubMed ID: 23645763
[TBL] [Abstract][Full Text] [Related]
26. Prognostic markers in resectable non-small cell lung cancer: a multivariate analysis.
Pelletier MP; Edwardes MD; Michel RP; Halwani F; Morin JE
Can J Surg; 2001 Jun; 44(3):180-8. PubMed ID: 11407827
[TBL] [Abstract][Full Text] [Related]
27. Immunohistochemical subtyping of nonsmall cell lung cancer not otherwise specified in fine-needle aspiration cytology: a retrospective study of 103 cases with surgical correlation.
Righi L; Graziano P; Fornari A; Rossi G; Barbareschi M; Cavazza A; Pelosi G; Scagliotti GV; Papotti M
Cancer; 2011 Aug; 117(15):3416-23. PubMed ID: 21246522
[TBL] [Abstract][Full Text] [Related]
28. Higher expression of EphA2 and ephrin-A1 is related to favorable clinicopathological features in pathological stage I non-small cell lung carcinoma.
Ishikawa M; Miyahara R; Sonobe M; Horiuchi M; Mennju T; Nakayama E; Kobayashi M; Kikuchi R; Kitamura J; Imamura N; Huang CL; Date H
Lung Cancer; 2012 Jun; 76(3):431-8. PubMed ID: 22236865
[TBL] [Abstract][Full Text] [Related]
29. Immunhistochemistry by means of widely agreed-upon markers (cytokeratins 5/6 and 7, p63, thyroid transcription factor-1, and vimentin) on small biopsies of non-small cell lung cancer effectively parallels the corresponding profiling and eventual diagnoses on surgical specimens.
Pelosi G; Rossi G; Bianchi F; Maisonneuve P; Galetta D; Sonzogni A; Veronesi G; Spaggiari L; Papotti M; Barbareschi M; Graziano P; Decensi A; Cavazza A; Viale G
J Thorac Oncol; 2011 Jun; 6(6):1039-49. PubMed ID: 21512408
[TBL] [Abstract][Full Text] [Related]
30. Clinical significance of insulin receptor substrate-I down-regulation in non-small cell lung cancer.
Han CH; Cho JY; Moon JT; Kim HJ; Kim SK; Shin DH; Chang J; Ahn CM; Kim SK; Chang YS
Oncol Rep; 2006 Dec; 16(6):1205-10. PubMed ID: 17089038
[TBL] [Abstract][Full Text] [Related]
31. Expression of maspin in non-small-cell lung cancer: correlation with clinical features.
Takanami I; Abiko T; Koizumi S
Clin Lung Cancer; 2008 Nov; 9(6):361-6. PubMed ID: 19073519
[TBL] [Abstract][Full Text] [Related]
32. Vascular endothelial growth factor A and vascular endothelial growth factor receptor 2 expression in non-small cell lung cancer patients: relation to prognosis.
Bonnesen B; Pappot H; Holmstav J; Skov BG
Lung Cancer; 2009 Dec; 66(3):314-8. PubMed ID: 19324448
[TBL] [Abstract][Full Text] [Related]
33. Activated epidermal growth factor receptor-Stat-3 signaling promotes tumor survival in vivo in non-small cell lung cancer.
Haura EB; Zheng Z; Song L; Cantor A; Bepler G
Clin Cancer Res; 2005 Dec; 11(23):8288-94. PubMed ID: 16322287
[TBL] [Abstract][Full Text] [Related]
34. The utility of p53 immunostaining of transbronchial biopsy specimens of lung cancer: p53 overexpression predicts poor prognosis and chemoresistance in advanced non-small cell lung cancer.
Kawasaki M; Nakanishi Y; Kuwano K; Yatsunami J; Takayama K; Hara N
Clin Cancer Res; 1997 Jul; 3(7):1195-200. PubMed ID: 9815799
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of the prognostic role of a panel of biomarkers in stage IB-IIIA non-small cell lung cancer patients.
Timotheadou E; Skarlos DV; Samantas E; Papadopoulos S; Murray S; Skrickova J; Christodoulou C; Papakostantinou C; Pectasides D; Papakostas P; Kaplanova J; Vrettou E; Karina M; Kosmidis P; Fountzilas G
Anticancer Res; 2007; 27(6C):4481-9. PubMed ID: 18214064
[TBL] [Abstract][Full Text] [Related]
36. Prognostic significance of MCM7 expression in the bronchial brushings of patients with non-small cell lung cancer (NSCLC).
Liu YZ; Jiang YY; Hao JJ; Lu SS; Zhang TT; Shang L; Cao J; Song X; Wang BS; Cai Y; Zhan QM; Wang MR
Lung Cancer; 2012 Jul; 77(1):176-82. PubMed ID: 22456526
[TBL] [Abstract][Full Text] [Related]
37. Molecular genetic alterations in thyroid transcription factor 1-negative lung adenocarcinoma in cytology specimens: A subset with aggressive behavior and a poor prognosis.
Rodriguez EF; VandenBussche CJ; Chowsilpa S; Maleki Z
Cancer Cytopathol; 2018 Oct; 126(10):853-859. PubMed ID: 30199148
[TBL] [Abstract][Full Text] [Related]
38. Prognostic value of thyroid transcription factor-1 in primary, resected, non-small cell lung carcinoma.
Puglisi F; Barbone F; Damante G; Bruckbauer M; Di Lauro V; Beltrami CA; Di Loreto C
Mod Pathol; 1999 Mar; 12(3):318-24. PubMed ID: 10102618
[TBL] [Abstract][Full Text] [Related]
39. ERCC1 expression by immunohistochemistry and EGFR mutations in resected non-small cell lung cancer.
Lee KH; Min HS; Han SW; Oh DY; Lee SH; Kim DW; Im SA; Chung DH; Kim YT; Kim TY; Heo DS; Bang YJ; Sung SW; Kim JH
Lung Cancer; 2008 Jun; 60(3):401-7. PubMed ID: 18036700
[TBL] [Abstract][Full Text] [Related]
40. Immunohistochemical analysis of C/EBPalpha in non-small cell lung cancer reveals frequent down-regulation in stage II and IIIA tumors: a correlative study of E3590.
Costa DB; Li S; Kocher O; Feins RH; Keller SM; Schiller JH; Johnson DH; Tenen DG; Halmos B
Lung Cancer; 2007 Apr; 56(1):97-103. PubMed ID: 17239984
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]